ARX
data caveat$191MCF+
Aroa Biosurgery
Medical Devices · Wound care
Myriad and Symphony extracellular matrix surgical products for tissue repair
Data HealthTrials1 of 2 active · stale enrollment
Cash data from Sept 2025 4C(6mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$21.3M
Sept 2025 4C
Runway
CF+Cash Flow Positive
Based on Sept 2025 4C
Market Cap
$191M
Burn Rate
—
Sept 2025 4C
Shares Outstanding
347M
Pipeline Assets
2
3M Price
ARX.ASX$0.550-20.3% 3M
Low $0.510High $0.710
Pipeline Assets (2)
Myriad MatrixSurgical soft tissue repair
ApprovedSymphonyComplex wound management
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Myriad Matrix
Surgical soft tissue repair
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-04-17 · 4-day lag
Short position
0.10%
arrow_drop_down-0.05% over 30 reports
Shares short
0.4M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Competitive Landscape
1 competitor trialPhase 2+ · Non-ASX
Surgical Soft Tissue Repair1 active trial
1 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
15 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
ACS Appl Mater Interfaces2026-04· Symphony
Biol Rev Camb Philos Soc2026-04· Symphony
Neural Regen Res2026-04· Symphony
Mol Neurodegener2026-03· Symphony
Catalysts (3)
Myriad US revenue growth update
UpcomingConfirmedremoveMed30 Apr 2026
SpeculativeremoveMed1 Feb 2027
SpeculativeMed
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(4)
2 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 1565d
Myriad Matrix™ and Myriad Morcells™
Myriad™ Augmented Soft Tissue Reconstruction Registry
Abdominal Wound Dehiscence · Necrotizing Soft Tissue Infection · Lower Extremity Wound +4 more
18 Years+
Primary endpoint Proportion of participants with treatment emergent adverse events during the study
ENROL800
no manual snapshots — enter via record_enrollment.py
Ph4Recruiting
Myriad™ applied in conjunction with NPWTNPWT Alone
Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures
Soft Tissue Defects · Soft Tissue Wounds · Traumatic Soft Tissue Defect
RandomizedOpen Label18 Years+
Primary endpoint Tissue Coverage
ENROL30
no manual snapshots — enter via record_enrollment.py